H.C. Wainwright Now Covering Asterias Biotherapeutics (AMEX:AST) With $11.0000 Target

June 20, 2018 - By James Guidry

Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) Logo

Why Has H.C. Wainwright Given Asterias Biotherapeutics (AMEX:AST) a $11.0000 Price Target

H.C. Wainwright revealed to investors in an analysts note that it started coverage on Asterias Biotherapeutics (AMEX:AST) stock, with “Buy” rating and a $11.0000 PT.

Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) Ratings Coverage

Among 2 analysts covering Asterias Biotherapeutics (AMEX:AST), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Asterias Biotherapeutics has $11.0 highest and $6.0 lowest target. $8.50’s average target is 365.75% above currents $1.825 stock price. Asterias Biotherapeutics had 8 analyst reports since January 8, 2018 according to SRatingsIntel. H.C. Wainwright maintained Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) on Monday, January 8 with “Buy” rating. H.C. Wainwright maintained the shares of AST in report on Friday, March 16 with “Buy” rating. H.C. Wainwright maintained Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) on Thursday, May 3 with “Buy” rating. The rating was initiated by H.C. Wainwright with “Buy” on Tuesday, June 19. The company was initiated on Thursday, February 22 by FBR Capital. The firm has “Buy” rating given on Wednesday, June 6 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, March 1 by FBR Capital.

The stock increased 4.29% or $0.075 during the last trading session, reaching $1.825. About 65,979 shares traded. Asterias Biotherapeutics, Inc. (AMEX:AST) has declined 52.94% since June 20, 2017 and is downtrending. It has underperformed by 65.51% the S&P500.

Analysts await Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) to report earnings on August, 13. They expect $-0.11 EPS, up 38.89 % or $0.07 from last year’s $-0.18 per share. After $-0.09 actual EPS reported by Asterias Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts 22.22 % negative EPS growth.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company has market cap of $100.39 million. The firm develops therapeutic products in the areas of neurology and oncology. It currently has negative earnings. The Company’s clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke.

Another recent and important Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) news was published by Equitiesfocus.com which published an article titled: “Asterias Biotherapeutics (AST) PT Set at $11.00 by HC Wainwright” on June 15, 2018.

Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: